Invasive trichosporonosis caused by Trichosporon asahii and other unusual Trichosporon species at a medical center in taiwan

Clinical Infectious Diseases

Volumn 49, Issue 1, 2009, Pages

  Ruan, Sheng Yuan ^a   Chien, Jung Yien ^a   Hsueh, Po Ren ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b Department of Laboratory Medicine ^*  (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FUNGUS ISOLATION; HUMAN; MALE; MENINGITIS; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MYCOSIS; NUCLEOTIDE SEQUENCE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SOFT TISSUE INFECTION; TAIWAN; TRICHOSPORON ASAHII; TRICHOSPORONOSIS;

ACADEMIC MEDICAL CENTERS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CHILD; CHILD, PRESCHOOL; DNA, FUNGAL; DNA, RIBOSOMAL SPACER; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOSES; SEQUENCE ANALYSIS, DNA; TAIWAN; TRICHOSPORON; YOUNG ADULT;

EID: 66949176205     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/599614     Document Type: Article

References (40)

1. Chagas-Neto TC, Chaves GM, Colombo AL. Update on the genus Trichosporon. Mycopathologia 2008; 166:121-32.
2. Haupt HM, Merz WG, Beschorner WE, Vaughan WP, Saral R. Colonization and infection with Trichosporon species in the immunosup- pressed host. J Infect Dis 1983; 147:199-203.
3. Rodrigues Gda S, de Faria RR, Guazzelli LS, Oliveira Fde M, Severo LC. Nosocomial infection due to Trichosporon asahii: clinical revision of 22 cases [in Spanish]. Rev Iberoam Micol 2006;23:85-9.
4. Gueho E, Improvisi L, de Hoog GS, Dupont B. Trichosporon on humans: a practical account. Mycoses 1994; 37:3-10.
5. Kontoyiannis DP, Torres HA, Chagua M, et al. Trichosporonosis in a tertiary care cancer center: risk factors, changing spectrum and determinants of outcome. Scand J Infect Dis 2004; 36:564-9.
6. Girmenia C, Pagano L, Martino B, et al. Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with he- matological malignancies: a retrospective multicenter study from Italy and review of the literature. J Clin Microbiol 2005;43:1818-28.
7. Cawley MJ, Braxton GR, Haith LR, et al. Trichosporon beigelii infection: experience in a regional burn center. Burns 2000; 26:483-6.
8. Krcmery V Jr, Mateicka F, Kunova A, et al. Hematogenous trichosporonosis in cancer patients: report of 12 cases including 5 during prophylaxis with itraconazol. Support Care Cancer 1999; 7:39-43.
9. Agirbasli H, Bilgen H, Ozcan SK, et al. Two possible cases of Trichosporon infections in bone-marrow-transplanted children: the first case of T. japonicum isolated from clinical specimens. Jpn J Infect Dis 2008;61:130-2.
10. Sugita T, Nishikawa A, Ikeda R, Shinoda T. Identification of medically relevant Trichosporon species based on sequences of internal transcribed spacer regions and construction of a database for Trichosporon identification. J Clin Microbiol 1999;37:1985-93.
11. Rodriguez-Tudela J, Diaz-Guerra T, Mellado E, et al. Susceptibility patterns and molecular identification of Trichosporon species. Antimicrob Agents Chemother 2005; 49:4026-34.
12. Sugita T, Nakajima M, Ikeda R, Matsushima T, Shinoda T. Sequence analysis of the ribosomal DNA intergenic spacer 1 regions of Tricho- sporon species. J Clin Microbiol 2002;40:1826-30.
13. Polacheck I, Salkin IF, Kitzes-Cohen R, Raz R. Endocarditis caused by Blastoschizomyces capitatus and taxonomic review of the genus. J Clin Microbiol 1992;30:2318-22.
14. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46:1813-21.
15. National Committee for Clinical Laboratory Standards. Reference method for broth microdilution antifungal susceptibility testing of yeasts: approved standard M27-A2. 2nd ed. Wayne, PA: National Committee for Clinical Laboratory Standards, 2002.
16. Pfaller MA, Boyken L, Hollis RJ, et al. In vitro susceptibility ofinvasive isolates of Candida spp. to anidulafungin, caspofungin, and micafun- gin: six years of global surveillance. J Clin Microbiol 2008; 46:150-6.
17. Pfaller MA, Diekema DJ, Rex JH, et al. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol 2006; 44:819-26.
18. Rex JH, Pfaller MA, Walsh TJ, et al. Antifungal susceptibility testing:practical aspects and current challenges. Clin Microbiol Rev 2001 ;14:643-58.
19. Gunn SR, Reveles XT, Hamlington JD, Sadkowski LC, Johnson-Pais TL, Jorgensen JH. Use of DNA sequencing analysis to confirm fungemia due to Trichosporon dermatis in a pediatric patient. J Clin Microbiol 2006; 44:1175-7.
20. Tashiro T, Nagai H, Kamberi P, et al. Disseminated Trichosporon beigelii infection in patients with malignant diseases: immunohistochemical study and review. Eur J Clin Microbiol Infect Dis 1994; 13:218-24.
21. Walsh TJ, Melcher GP, Lee JW, Pizzo PA. Infections due to Trichosporon species: new concepts in mycology, pathogenesis, diagnosis and treatment. Curr Top Med Mycol 1993;5:79-113.
22. Keay S, Denning DW, Stevens DA. Endocarditis due to Trichosporon beigelii: in vitro susceptibility of isolates and review. Rev Infect Dis 1991; 13:383-6.
23. Mooty MY, Kanj SS, Obeid MY, Hassan GY, Araj GF. A case of Tri- chosporon beigelii endocarditis. Eur J Clin Microbiol Infect Dis 2001 ; 20:139-42.
24. Ramos JM, Cuenca-Estrella M, Gutierrez F, Elia M, Rodriguez-Tudela JL. Clinical case of endocarditis due to Trichosporon inkin and anti- fungal susceptibility profile of the organism. J Clin Microbiol 2004; 42:2341-4.
25. Gross JW, Kan VL. Trichosporon asahii infection in an advanced AIDS patient and literature review. AIDS 2008; 22:793-5.
26. Leaf HL, Simberkoff MS. Invasive trichosporonosis in a patient with the acquired immunodeficiency syndrome. J Infect Dis 1989; 160:356-7.
27. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 2003;3:685-702.
28. Schwartz RA. Superficial fungal infections. Lancet 2004;364:1173- 82.
29. Kalter DC, Tschen JA, Cernoch PL, et al. Genital white piedra: epidemiology, microbiology, and therapy. J Am Acad Dermatol 1986;14:982- 93.
30. Ando M, Suga M, Nishiura Y, Miyajima M. Summer-type hypersen- sitivity pneumonitis. Intern Med 1995; 34:707-12.
31. Anaissie E, Gokaslan A, Hachem R, et al. Azole therapy for trichospo- ronosis: clinical evaluation of eight patients, experimental therapy for murine infection, and review. Clin Infect Dis 1992; 15:781-7.
32. Kamberi P, Atsuro H, Takayoshi T, Masaru N. Efficacy of amphotericin B and azoles alone and in combination against disseminated trichospo- ronosis in neutropenic mice. Chemotherapy 1998; 44:55-62.
33. Li HM, Du HT, Liu W, Wan Z, Li RY. Microbiological characteristics of medically important Trichosporon species. Mycopathologia 2005; 160:217-25.
34. Antachopoulos C, Papakonstantinou E, Dotis J, et al. Fungemia due to Trichosporon asahii in a neutropenic child refractory to amphoteri- cin B: clearance with voriconazole. J Pediatr Hematol Oncol 2005;27:283-5.
35. Asada N, Uryu H, Koseki M, et al. Successful treatment of breakthrough Trichosporon asahii fungemia with voriconazole in a patient with acute myeloid leukemia. Clin Infect Dis 2006; 43:e39-41.
36. Fournier S, Pavageau W, Feuillhade M, et al. Use of voriconazole to successfully treat disseminated Trichosporon asahii infection in a patient with acute myeloid leukaemia. Eur J Clin Microbiol Infect Dis 2002; 21:892-6.
37. Serena C, Gilgado F, Marine M, Pastor FJ, Guarro J. Efficacy of vor- iconazole in a guinea pig model of invasive trichosporonosis. Antimicrob Agents Chemother 2006; 50:2240-3.
38. Bayramoglu G, Sonmez M, Tosun I, Aydin K, Aydin F. Breakthrough Trichosporon asahii fungemia in neutropenic patient with acute leukemia while receiving caspofungin. Infection 2008; 36:68-70.
39. Matsue K, Uryu H, Koseki M, Asada N, Takeuchi M. Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin. Clin Infect Dis 2006; 42:753-7.
40. Ruan SY, Huang YT, Chu CC, Yu CJ, Hsueh PR. Candida glabrata fungaemia in a tertiary centre in Taiwan: antifungal susceptibility and outcomes. Int J Antimicrob Agents 2009 (Epub ahead of print).